Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
Novo Nordisk today announced that the Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for expanded use of Tresiba® (insulin degludec) in children and adolescents aged one to 17 years with diabetes. Once the European Commission approves the licence extension, physicians in the European Union will be able to prescribe insulin degludec to children and adolescents aged one to 17 with type 1 and type 2 diabetes.
According to the International Diabetes Federation, an estimated 497,100 children under 15 years are living globally with type 1 diabetes and rates of type 2 diabetes among children are also on the increase[1].
"When treating children and adolescents with diabetes, getting patients to target while minimising side effects is always a priority," said Dr Nandu Thalange, paediatric endocrinologist at Norfolk and Norwich University Hospital, Norwich, United Kingdom and the lead study investigator of the BEGIN® YOUNG 1 trial. "This latest CHMP recommendation for insulin degludec offers patients between the ages of one and 17 a once-daily basal insulin which allows patients to get to target with a reduced risk of hyperglycemia with ketosis versus insulin detemir."
http://www.prnewswire.co.uk/news-re...ment-of-children-with-diabetes-286349591.html
According to the International Diabetes Federation, an estimated 497,100 children under 15 years are living globally with type 1 diabetes and rates of type 2 diabetes among children are also on the increase[1].
"When treating children and adolescents with diabetes, getting patients to target while minimising side effects is always a priority," said Dr Nandu Thalange, paediatric endocrinologist at Norfolk and Norwich University Hospital, Norwich, United Kingdom and the lead study investigator of the BEGIN® YOUNG 1 trial. "This latest CHMP recommendation for insulin degludec offers patients between the ages of one and 17 a once-daily basal insulin which allows patients to get to target with a reduced risk of hyperglycemia with ketosis versus insulin detemir."
http://www.prnewswire.co.uk/news-re...ment-of-children-with-diabetes-286349591.html